Insights Into the Diagnosis and Treatment of Lysosomal Storage Diseases
Open Access
- 1 March 2003
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 60 (3) , 322-328
- https://doi.org/10.1001/archneur.60.3.322
Abstract
Lysosomal storage diseases (LSDs) are a group of genetic disorders that result from defective lysosomal metabolism or export of naturally occurring compounds. Signs and symptoms are variable both within and between disorders depending on the location and extent of storage. Many patients develop neurologic symptoms that become obvious from the newborn period to adulthood. Diagnosis of suspected patients can usually be made by measuring the activity of an enzyme or concentration of a metabolite in easily obtained tissue samples. Based on the considerable diagnostic experience of our laboratory, we aid the physician in selecting the appropriate tests to perform. Hematopoietic stem cell transplantation and enzyme replacement therapy are already available or in clinical trials for a number of LSDs. Early diagnosis is critical, especially since those patients who are treated before significant symptoms arise have the best chance for a positive outcome.Keywords
This publication has 11 references indexed in Scilit:
- Tandem mass spectrometry: the tool of choice for diagnosing inborn errors of metabolism?British Journal of Biomedical Science, 2002
- Niemann-Pick Disease Type C: Spectrum of HE1 Mutations and Genotype/Phenotype Correlations in the NPC2 GroupAmerican Journal of Human Genetics, 2001
- Niemann-Pick C1 Disease: Correlations between NPC1 Mutations, Levels of NPC1 Protein, and Phenotypes Emphasize the Functional Significance of the Putative Sterol-Sensing Domain and of the Cysteine-Rich Luminal LoopAmerican Journal of Human Genetics, 2001
- Enzyme-Replacement Therapy in Mucopolysaccharidosis INew England Journal of Medicine, 2001
- Krabbe Disease: Genetic Aspects and Progress toward TherapyMolecular Genetics and Metabolism, 2000
- N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivoBiochemical Pharmacology, 2000
- Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndromeCurrent Opinion in Hematology, 1999
- Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N -butyldeoxynojirimycinProceedings of the National Academy of Sciences, 1999
- Prevalence of Lysosomal Storage DisordersJAMA, 1999
- Enzyme therapy for Gaucher disease: the first 5 yearsBlood Reviews, 1998